…since enactment of the Medicare Modernization Act of 2003, a branded-drug company can obtain only one 30-month stay against a given challenger for a given drug, regardless of how many patents protect the drug in question.
The above is almost always true, but there is one exception—what is it?
Hint 1: The MMA change to Hatch-Waxman grants no 30-month stay for any patent added to the Orange Book after a given Paragraph-IV challenge is filed.
Hint 2: The exception in the quiz hardly ever comes into play in practice.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.